Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis
暂无分享,去创建一个
[1] Eric S. Lander,et al. Genomic analysis of metastasis reveals an essential role for RhoC , 2000, Nature.
[2] R. Cummings,et al. Noncovalent Association of P-selectin Glycoprotein Ligand-1 and Minimal Determinants for Binding to P-selectin* , 2000, The Journal of Biological Chemistry.
[3] H. Tsukada,et al. Possible role of immune surveillance at the initial phase of metastasis produced by B16BL6 melanoma cells , 2000, FEBS letters.
[4] Susanne M. Smorenburg,et al. The Effects of Unfractionated Heparin on Survival in Patients with Malignancy – A Systematic Review , 1999, Thrombosis and Haemostasis.
[5] C. Stein,et al. Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides , 1999, International journal of cancer.
[6] M. Levine,et al. Do Heparins Do More than Just Treat Thrombosis? The Influence of Heparins on Cancer Spread , 1999, Thrombosis and Haemostasis.
[7] A. Varki,et al. Distinct selectin ligands on colon carcinoma mucins can mediate pathological interactions among platelets, leukocytes, and endothelium. , 1999, The American journal of pathology.
[8] W. Cowden,et al. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. , 1999, Cancer research.
[9] O. Pappo,et al. Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis , 1999, Nature Medicine.
[10] B. Echtenacher,et al. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. , 1999, Cancer research.
[11] H. Engelberg. Actions of heparin that may affect the malignant process , 1999, Cancer.
[12] M. Raderer,et al. Inhibition of metastases by anticoagulants. , 1999, Journal of the National Cancer Institute.
[13] K. Holme,et al. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. , 1999, Advances in pharmacology.
[14] A. Varki,et al. P-selectin deficiency attenuates tumor growth and metastasis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[15] L. Zacharski,et al. Heparin and Cancer , 1998, Thrombosis and Haemostasis.
[16] A. Varki,et al. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. , 1998, The Journal of clinical investigation.
[17] H. Rauschecker,et al. Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983-1987). European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group. , 1997, European journal of cancer.
[18] A. Varki,et al. Perspectives Series: Cell Adhesion in Vascular Biology Selectin Ligands: Will the Real Ones Please Stand Up? , 2022 .
[19] Jeffrey S. Ginsberg,et al. Management of venous thromboembolism. , 1996, The New England journal of medicine.
[20] S. Hakomori. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. , 1996, Cancer research.
[21] G S Kansas,et al. Selectins and their ligands: current concepts and controversies. , 1996, Blood.
[22] M. Salmivirta,et al. Heparan sulfate : a piece of information , 2004 .
[23] K. Holme,et al. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties. , 1996, Glycobiology.
[24] F. Marcucci,et al. Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival. , 1996, Invasion & metastasis.
[25] A. Varki,et al. Differential colon cancer cell adhesion to E-, P-, and L-selectin: role of mucin-type glycoproteins. , 1995, Cancer research.
[26] K. Handa,et al. P-selectin-dependent adhesion of human cancer-cells - requirement for coexpression of a psgl-1-like core protein and the glycosylation process for sialosyl-le(x) or sialosyl-le(a). , 1995, International journal of oncology.
[27] T. Irimura,et al. Characterization of human colon carcinoma variant cells selected for sialyl Lex carbohydrate antigen: liver colonization and adhesion to vascular endothelial cells. , 1995, Experimental cell research.
[28] G. Pellegrini,et al. P-selectin induces the expression of tissue factor on monocytes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[29] A. Varki,et al. Selectin ligands. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[30] E. Lemarié,et al. Subcutaneous heparin treatment increases survival in small cell lung cancer , 1994, Cancer.
[31] T. Peretz,et al. Inhibition of tumor metastasis by heparanase inhibiting species of heparin. , 1994, Invasion & metastasis.
[32] J. P. Stone,et al. P-selectin mediates adhesion of platelets to neuroblastoma and small cell lung cancer. , 1993, The Journal of clinical investigation.
[33] T. Irimura,et al. Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. , 1993, Cancer research.
[34] R. Kannagi,et al. Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. , 1993, Cancer research.
[35] L. Fielding,et al. Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma , 1992, The Lancet.
[36] D. Sutherland,et al. Cleavage of the cell-surface O-sialoglycoproteins CD34, CD43, CD44, and CD45 by a novel glycoprotease from Pasteurella haemolytica. , 1992, Journal of immunology.
[37] J. Folkman. Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction. , 1990, Cancer metastasis reviews.
[38] I. Fidler,et al. Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. , 1990, Cancer research.
[39] T Irimura,et al. Increased expression of sialyl-dimeric LeX antigen in liver metastases of human colorectal carcinoma. , 1989, Cancer research.
[40] P. B. Weisz,et al. Control of angiogenesis with synthetic heparin substitutes. , 1989, Science.
[41] D. Agard,et al. Fluorescence microscopy in three dimensions. , 1989, Methods in cell biology.
[42] I. Fidler,et al. Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. , 1988, Biochimica et biophysica acta.
[43] L. Zacharski. Basis for selection of anticoagulant drugs for therapeutic trials in human malignancy. , 1986, Haemostasis.
[44] A. Tohgo,et al. Platelet-aggregating activities of metastasizing tumor cells. V. In situ roles of platelets in hematogenous metastases. , 1986, Invasion & metastasis.
[45] W. Henderson,et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate: Final Report of VA cooperative study # 75 , 1984, Cancer.
[46] S. Karpatkin,et al. Role of platelets in tumor cell metastases. , 1981, Annals of the New York Academy of Sciences.